Should I buy or sell Tenax Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TENX shares. View TENX analyst ratings or view top-rated stocks .

What is Tenax Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 1 year target prices for Tenax Therapeutics' shares. Their TENX share price targets range from $480.00 to $480.00. On average, they predict the company's stock price to reach $480.00 in the next twelve months. This suggests a possible upside of 13,123.1% from the stock's current price. View analysts price targets for TENX or view top-rated stocks among Wall Street analysts .

How have TENX shares performed in 2024?

Tenax Therapeutics' stock was trading at $21.9680 at the beginning of 2024. Since then, TENX stock has decreased by 83.5% and is now trading at $3.63. View the best growth stocks for 2024 here .

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 49,000 shares, an increase of 33.5% from the March 15th total of 36,700 shares. Based on an average trading volume of 340,200 shares, the short-interest ratio is currently 0.1 days. Currently, 2.6% of the company's shares are sold short. View Tenax Therapeutics' Short Interest .

When is Tenax Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TENX earnings forecast .

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) posted its quarterly earnings data on Tuesday, November, 16th. The specialty pharmaceutical company reported ($240.00) earnings per share for the quarter, missing analysts' consensus estimates of ($208.00) by $32.00.

When did Tenax Therapeutics' stock split?

Tenax Therapeutics shares reverse split on the morning of Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE) , AcelRx Pharmaceuticals (ACRX) , Inovio Pharmaceuticals (INO) , Idera Pharmaceuticals (IDRA) , NVIDIA (NVDA) , SCYNEXIS (SCYX) , Verastem (VSTM) , Bank of Hawaii (BOH) , Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO) .

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TENX Stock Alerts

$3.63

-0.05 (-1.36%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.57
▼
$3.78
50-Day Range: $3.59
▼
$5.01
52-Week Range: $3.48
▼
$61.20

Volume: 13,788 shs
Average Volume: 46,502 shs
Market Capitalization: $7.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $480.00

Get Tenax Therapeutics alerts:

Tenax Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 13,123.1% Upside
$480.00 Price Target
Short Interest: Healthy
2.62% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.18
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($7.43) to ($3.63) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.52 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Tenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Tenax Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.62% of the float of Tenax Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tenax Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Tenax Therapeutics has recently increased by 33.51%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tenax Therapeutics does not currently pay a dividend.
Dividend Growth
Tenax Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TENX.

3.4

News and Social Media Coverage

News Sentiment
Tenax Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Tenax Therapeutics this week, compared to 1 article on an average week.
Search Interest
12 people have searched for TENX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.85% of the stock of Tenax Therapeutics is held by insiders.
Percentage Held by Institutions
Only 1.67% of the stock of Tenax Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Tenax Therapeutics are expected to grow in the coming year, from ($7.43) to ($3.63) per share.
Price to Book Value per Share Ratio
Tenax Therapeutics has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Tenax Therapeutics Stock (NASDAQ:TENX)

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TENX Stock News Headlines

April 15, 2024 | americanbankingnews.com

Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Rises By 33.5%

April 9, 2024 | finance.yahoo.com

TENX: 2023 Financial Results

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 9, 2024 | globenewswire.com

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

March 28, 2024 | benzinga.com

Tenax Therapeutics: Q4 Earnings Insights

March 28, 2024 | msn.com

TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023

March 28, 2024 | globenewswire.com

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

March 20, 2024 | bizjournals.com

Former public company CEO now leads RTP firm

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 12, 2024 | globenewswire.com

Tenax Therapeutics to Present at the 36th Annual Roth Conference

February 29, 2024 | globenewswire.com

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

February 20, 2024 | finance.yahoo.com

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

February 20, 2024 | globenewswire.com

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

February 12, 2024 | finance.yahoo.com

TENX: First Patient Enrolled

February 9, 2024 | bizjournals.com

Chapel Hill pharma pushing PHT treatment opens $9M stock offering

February 8, 2024 | msn.com

Why Tenax Therapeutics (TENX) Stock Is Getting Obliterated

February 8, 2024 | marketwatch.com

Tenax Therapeutics Shares Plummet Premarket After Stock Offering

February 8, 2024 | markets.businessinsider.com

Tenax Therapeutics Announces Pricing Of About $9 Mln Offering Of Shares, Warrants; Stock Tanks 63%

February 8, 2024 | finance.yahoo.com

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

February 8, 2024 | investorplace.com

Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?

February 8, 2024 | finance.yahoo.com

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

February 7, 2024 | msn.com

Tenax Therapeutics Granted Patent for Heart Treatment Drugs

February 6, 2024 | marketwatch.com

Tenax Shares Surge After Acceptance of Patent Application

February 6, 2024 | msn.com

Tenax surges after patent win for heart failure therapy

February 6, 2024 | finance.yahoo.com

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

January 3, 2024 | benzinga.com

Tenax Therapeutics Stock (NASDAQ:TENX), Short Interest Report

January 3, 2024 | finance.yahoo.com

Breakeven On The Horizon For Tenax Therapeutics, Inc. (NASDAQ:TENX)

See More Headlines

Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/16/2021
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TENX
CUSIP: N/A
CIK: 34956
Web: www.tenaxthera.com
Phone: 919-855-2100
Fax: 919-855-2133
Employees: 7
Year Founded: 1967

Price Target and Rating

Average Stock Price Target: $480.00
High Stock Price Target: $480.00
Low Stock Price Target: $480.00
Potential Upside/Downside: +13,123.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,710,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -65.79%
Return on Assets: -58.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.26
Quick Ratio: 3.26

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $27.15 per share
Price / Book: 0.13

Miscellaneous

Outstanding Shares: 1,960,000
Free Float: 1,922,000
Market Cap: $7.11 million
Optionable: Not Optionable
Beta: 2.25

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Christopher T. Giordano (Age 49)
CEO, President & Director
Comp: $442.12k
Dr. Stuart Rich M.D. (Age 74)
Chief Medical Officer & Director
Comp: $354.02k
Mr. Lawrence R. Hoffman CPA (Age 69)
Esq., Interim Chief Financial Officer
Mr. Doug Randall
Executive Vice President of Commercial & Business Operations
Dr. Douglas Hay
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TENX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TENX shares.
View TENX analyst ratings or view top-rated stocks.
What is Tenax Therapeutics' stock price target for 2024?: 1 Wall Street analysts have issued 1 year target prices for Tenax Therapeutics' shares. Their TENX share price targets range from $480.00 to $480.00. On average, they predict the company's stock price to reach $480.00 in the next twelve months. This suggests a possible upside of 13,123.1% from the stock's current price.
View analysts price targets for TENX or view top-rated stocks among Wall Street analysts.
How have TENX shares performed in 2024?: Tenax Therapeutics' stock was trading at $21.9680 at the beginning of 2024. Since then, TENX stock has decreased by 83.5% and is now trading at $3.63.
View the best growth stocks for 2024 here.
Are investors shorting Tenax Therapeutics?: Tenax Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 49,000 shares, an increase of 33.5% from the March 15th total of 36,700 shares. Based on an average trading volume of 340,200 shares, the short-interest ratio is currently 0.1 days. Currently, 2.6% of the company's shares are sold short.
View Tenax Therapeutics' Short Interest.
When is Tenax Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our TENX earnings forecast.

How were Tenax Therapeutics' earnings last quarter?: Tenax Therapeutics, Inc. (NASDAQ:TENX) posted its quarterly earnings data on Tuesday, November, 16th. The specialty pharmaceutical company reported ($240.00) earnings per share for the quarter, missing analysts' consensus estimates of ($208.00) by $32.00.
When did Tenax Therapeutics' stock split?: Tenax Therapeutics shares reverse split on the morning of Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
What other stocks do shareholders of Tenax Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).
How do I buy shares of Tenax Therapeutics?: Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TENX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tenax Therapeutics (TENX) Stock Price, News & Analysis

Tenax Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Tenax Therapeutics Stock (NASDAQ:TENX)

TENX Stock Price History

TENX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

TENX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™